In a filing, Beam Therapeutics Inc revealed its Chief Legal Officer Bellon Christine unloaded Company’s shares for reported $0.1 million on Apr 01 ’25. In the deal valued at $18.35 per share,5,674 shares were sold. As a result of this transaction, Bellon Christine now holds 117,294 shares worth roughly $2.24 million.
Then, Evans John M. sold 30,663 shares, generating $562,684 in total proceeds. Upon selling the shares at $18.35, the CEO now owns 986,249 shares.
Before that, Ciaramella Giuseppe sold 7,434 shares. Beam Therapeutics Inc shares valued at $136,418 were divested by the President at a price of $18.35 per share. As a result of the transaction, Ciaramella Giuseppe now holds 190,216 shares, worth roughly $3.64 million.
BofA Securities upgraded its Beam Therapeutics Inc [BEAM] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who increased its forecast for the stock in early March from “a Sector perform” to “a Sector outperform”. Cantor Fitzgerald also remained covering BEAM and has increased its forecast on January 29, 2025 with a “an Overweight” recommendation from previously “Neutral” rating. Leerink Partners revised its rating on November 06, 2024. It rated BEAM as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of BEAM
On Tuesday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock jump 4.88% to $19.13. Over the last five days, the stock has gained 12.53%. Beam Therapeutics Inc shares have fallen nearly -22.86% since the year began. Nevertheless, the stocks have fallen -21.31% over the past one year. While a 52-week high of $35.25 was reached on 02/18/25, a 52-week low of $13.52 was recorded on 04/07/25. SMA at 50 days reached $23.55, while 200 days put it at $25.19.
Levels Of Support And Resistance For BEAM Stock
The 24-hour chart illustrates a support level at 18.54, which if violated will result in even more drops to 17.96. On the upside, there is a resistance level at 19.51. A further resistance level may holdings at 19.90. The Relative Strength Index (RSI) on the 14-day chart is 49.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.57, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 5.80%. Stochastics %K at 72.56% indicates the stock is a holding.
How much short interest is there in Beam Therapeutics Inc?
A steep rise in short interest was recorded in Beam Therapeutics Inc stocks on 2025-03-31, growing by 4.75 million shares to a total of 14.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 9.99 million shares. There was a rise of 32.2%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
